Open AccessRifampin Reduces the Plasma Concentrations of Oral and Intravenous Hydromorphone in Healthy Volunteers
Author(s) -
Terhi J. Lohela,
Satu Poikola,
Mikko Neuvonen,
Mikko Niemi,
Janne T. Backman,
Klaus T. Olkkola,
Tuomas Lilius
Publication year - 2020
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.404
H-Index - 201
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1213/ane.0000000000005229
Subject(s) - hydromorphone , medicine , pharmacokinetics , pharmacodynamics , crossover study , placebo , anesthesia , pharmacology , bioavailability , dosing , confidence interval , oral administration , opioid , receptor , alternative medicine , pathology
Several opioids are metabolized by the inducible cytochrome P450 (CYP) 3A isozymes. Coadministration with strong inducers of drug metabolism, such as rifampin, can dramatically reduce systemic exposure to these opioids. As the CYP metabolism of hydromorphone is of minor importance, we studied in healthy volunteers whether hydromorphone would be an effective analgesic for patients who concomitantly receive the prototypical enzyme inducer rifampin.